MX9605613A - Procedimiento para preparar formas anhidras e hidratadas de derivados de piperidina antihistaminica, polimorfos y pseudomorfos de los mismos. - Google Patents

Procedimiento para preparar formas anhidras e hidratadas de derivados de piperidina antihistaminica, polimorfos y pseudomorfos de los mismos.

Info

Publication number
MX9605613A
MX9605613A MX9605613A MX9605613A MX9605613A MX 9605613 A MX9605613 A MX 9605613A MX 9605613 A MX9605613 A MX 9605613A MX 9605613 A MX9605613 A MX 9605613A MX 9605613 A MX9605613 A MX 9605613A
Authority
MX
Mexico
Prior art keywords
polymorphs
processes
pseudormophs
piperidine derivatives
preparing anhydrous
Prior art date
Application number
MX9605613A
Other languages
English (en)
Inventor
Daniel Randolph Henton
Frederick Joseph Mccarty
Susan Irene Tripp
Jill Elizabeth Dewitt
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26937420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9605613(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Publication of MX9605613A publication Critical patent/MX9605613A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion se refiere a procedimientos novedosos para preparar formas anhidras e hidratadas de derivados de piperidina, sus polimorfos y pseudomorfos de las formulas (I) y (II), que son utiles como antihistaminas, agentes antialérgicos y broquiodilatadores.
MX9605613A 1994-05-18 1995-04-28 Procedimiento para preparar formas anhidras e hidratadas de derivados de piperidina antihistaminica, polimorfos y pseudomorfos de los mismos. MX9605613A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24573194A 1994-05-18 1994-05-18
US41716195A 1995-04-11 1995-04-11
PCT/US1995/004942 WO1995031437A1 (en) 1994-05-18 1995-04-28 Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof

Publications (1)

Publication Number Publication Date
MX9605613A true MX9605613A (es) 1998-05-31

Family

ID=26937420

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9605613A MX9605613A (es) 1994-05-18 1995-04-28 Procedimiento para preparar formas anhidras e hidratadas de derivados de piperidina antihistaminica, polimorfos y pseudomorfos de los mismos.

Country Status (18)

Country Link
US (12) US20010025106A1 (es)
EP (3) EP1178041A1 (es)
JP (7) JPH10500134A (es)
CN (3) CN1148849A (es)
AT (1) ATE220667T1 (es)
AU (1) AU693892B2 (es)
CA (3) CA2449419C (es)
DE (1) DE69527429T2 (es)
DK (1) DK0766668T3 (es)
ES (1) ES2176329T3 (es)
FI (1) FI964565A (es)
HK (2) HK1098467A1 (es)
HU (1) HU227676B1 (es)
IL (3) IL134917A (es)
MX (1) MX9605613A (es)
NO (1) NO315319B1 (es)
PT (1) PT766668E (es)
WO (1) WO1995031437A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9400555D0 (en) * 1994-01-13 1994-03-09 Short Brothers Plc Boundery layer control in aerodynamic low drag structures
PT766668E (pt) 1994-05-18 2002-11-29 Aventis Pharma Inc Processos para a preparacao de formas anidras e hidratadas de derivados antihistaminicos da piperidina e de polimorfos e pseudomorfos destes
KR100405116B1 (ko) * 1995-02-28 2004-02-05 아벤티스 파마슈티칼스 인크. 피페리디노알칸올화합물에대한약제학적조성물
CZ295461B6 (cs) * 1997-08-26 2005-08-17 Aventis Pharmaceuticals Inc. Farmaceutický prostředek ve formě dvouvrstvé tablety
IN191492B (es) * 1999-05-25 2003-12-06 Ranbaxy Lab Ltd
US6613906B1 (en) 2000-06-06 2003-09-02 Geneva Pharmaceuticals, Inc. Crystal modification
CH695216A5 (de) * 2001-02-23 2006-01-31 Cilag Ag Verfahren zur Herstellung eines nicht hydratisierten Salzes eines Piperidinderivats und eine so erhältliche neue kristalline Form eines solchen Salzes.
US20030021849A1 (en) * 2001-04-09 2003-01-30 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
SK13822003A3 (sk) * 2001-04-09 2004-09-08 Teva Pharmaceutical Industries Ltd. Polymorfné formy chloridu fexofenadínu
JP2005507374A (ja) * 2001-06-18 2005-03-17 ドクター・レディーズ・ラボラトリーズ・リミテッド 新規な型の４−［４−［４−（ヒドロキシジフェニルメチル）−１−ピペリジニル］−１−ヒドロキシブチル］−α，α−ジメチルベンゼン酢酸及びその塩酸塩
US7700779B2 (en) * 2001-06-18 2010-04-20 Dr. Reddy's Laboratories Limited Crystalline forms of fexofenadine and its hydrochloride
ATE389405T1 (de) * 2001-07-31 2008-04-15 Texcontor Ets Fexofenadine hydrochlorid polymorph
US20030158227A1 (en) * 2001-11-08 2003-08-21 Barnaba Krochmal Polymorphs of fexofenadine base
JP2005532356A (ja) * 2002-06-10 2005-10-27 テバ ファーマシューティカル インダストリーズ リミティド 塩酸フェキソフェナジンの多型体ｘｖｉ
JP3910907B2 (ja) * 2002-10-29 2007-04-25 新光電気工業株式会社 キャパシタ素子及びこの製造方法、半導体装置用基板、並びに半導体装置
WO2005005447A2 (en) 2003-07-03 2005-01-20 Teva Pharmaceutical Industries Ltd. Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
GB0319935D0 (en) * 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
WO2005102999A2 (en) * 2004-04-26 2005-11-03 Teva Pharmaceutical Industries Ltd. Crystalline forms of fexofenadine hydrochloride and processes for their preparation
ITMI20041143A1 (it) * 2004-06-08 2004-09-08 Dipharma Spa Polimorfi di fexofenadina e procedimento per la loro preparazione
EP1616861A3 (en) * 2004-06-15 2006-02-08 Dipharma S.p.A. A process for the preparation of keto compounds
ITMI20041568A1 (it) * 2004-07-30 2004-10-30 Dipharma Spa "polimorfi di fexofenadina base"
WO2006037042A1 (en) * 2004-09-28 2006-04-06 Teva Pharmaceutical Industries Ltd. Fexofenadine crystal form and processes for its preparation thereof
DOP2006000274A (es) * 2005-12-14 2007-10-15 Sanofi Aventis Us Llc Formulación de suspensión de fexofenadina
AU2007272951A1 (en) * 2006-07-11 2008-01-17 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
US20090076080A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched fexofenadine
EP2105134A1 (en) 2008-03-24 2009-09-30 Ranbaxy Laboratories Limited Stable amorphous fexofenadine hydrochloride
WO2010083360A2 (en) * 2009-01-16 2010-07-22 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
JP2013510113A (ja) 2009-11-06 2013-03-21 ビーエーエスエフ ソシエタス・ヨーロピア ４−ヒドロキシ安息香酸及び選択された殺有害生物剤の結晶複合体
IT1400965B1 (it) * 2010-06-15 2013-07-05 Dipharma Francis Srl Polimorfi di fexofenadina
WO2011158262A1 (en) 2010-06-15 2011-12-22 Chemelectiva S.R.L. Polymorphic form of fexofenadine hydrochloride, intermediates and process for its preparation
US9420872B2 (en) * 2010-08-23 2016-08-23 Jason Bird Apparatus and system for holding game-calling devices
JP2012087100A (ja) * 2010-10-21 2012-05-10 Sumitomo Chemical Co Ltd 形態ｉのフェキソフェナジン一塩酸塩の製造方法
CN104072402B (zh) * 2014-07-16 2016-08-17 昆山龙灯瑞迪制药有限公司 一种新结晶形式的盐酸非索非那定化合物及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US631375A (en) * 1899-04-12 1899-08-22 Ephraim Musselman Face-protector.
US3448152A (en) * 1966-11-03 1969-06-03 Jefferson Chem Co Inc Amine recovery
US3878217A (en) * 1972-01-28 1975-04-15 Richardson Merrell Inc Alpha-aryl-4-substituted piperidinoalkanol derivatives
BE794598A (fr) 1972-01-28 1973-05-16 Richardson Merrell Inc Nouveaux derives olefiniques de piperidines substituees en 4 et leur procede de preparation
US3965257A (en) 1972-01-28 1976-06-22 Richardson-Merrell Inc. Compositions and methods for the treatment of the symptoms of histamine induced allergic reactions
US4285958A (en) 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkylene ketones, pharmaceutical compositions thereof and method of use thereof
US4254129A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4285957A (en) * 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof
US4254130A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
IL63968A (en) 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4742175A (en) 1986-05-07 1988-05-03 Merrell Dow Pharmaceuticals Inc. Preparation of polymorphically pure terfenadine
JPH02213431A (ja) * 1989-02-13 1990-08-24 Kobe Steel Ltd ＳｉＣウィスカ強化Ａｌ合金複合材料
DE4034218A1 (de) 1990-10-27 1992-04-30 Merck Patent Gmbh Verfahren zur herstellung von carebastin
TW198008B (es) 1991-04-08 1993-01-11 Green Cross Corp
EP0635004B1 (en) * 1992-04-10 2002-07-17 Merrell Pharmaceuticals Inc. 4-diphenylmethyl piperidine derivatives and process for their preparation
US5631375A (en) 1992-04-10 1997-05-20 Merrell Pharmaceuticals, Inc. Process for piperidine derivatives
DK0639976T3 (da) 1992-05-11 1999-02-15 Merrell Pharma Inc Anvendelse af terfenadin-derivater som antihistaminika i patienter med leversygdomme
CA2141572C (en) 1992-08-03 2001-02-06 James W. Young Terfenadine metabolites and their optically pure isomers for treating allergic disorders
US5315016A (en) 1992-10-13 1994-05-24 Nycomed Dak A/S Process for preparing pure podophyllotoxin
EP1369409B1 (en) 1993-06-24 2006-04-05 AMR Technology, Inc. Process for preparing compounds useful as intermediates
CA2254506C (en) 1993-06-24 2000-11-28 Albany Molecular Research, Inc. Piperidine derivatives and process for their production
NZ267830A (en) 1993-06-25 1998-05-27 Merrell Pharma Inc Preparation of 4-diphenylmethyl or 4-diphenylmethoxy piperidine derivatives and intermediates therefor
US6147216A (en) 1993-06-25 2000-11-14 Merrell Pharmaceuticals Inc. Intermediates useful for the preparation of antihistaminic piperidine derivatives
PT766668E (pt) * 1994-05-18 2002-11-29 Aventis Pharma Inc Processos para a preparacao de formas anidras e hidratadas de derivados antihistaminicos da piperidina e de polimorfos e pseudomorfos destes
US5576610A (en) 1994-07-05 1996-11-19 Motorola, Inc. Method and apparatus for determining battery characteristics
KR100405116B1 (ko) 1995-02-28 2004-02-05 아벤티스 파마슈티칼스 인크. 피페리디노알칸올화합물에대한약제학적조성물
IL134772A (en) 1995-02-28 2002-02-10 Aventis Pharma Inc Pharmaceutical compositions of piperidinoalkanol compounds in solid unit dosage form
US5574045A (en) 1995-06-06 1996-11-12 Hoechst Marion Roussel, Inc. Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
CZ295461B6 (cs) 1997-08-26 2005-08-17 Aventis Pharmaceuticals Inc. Farmaceutický prostředek ve formě dvouvrstvé tablety
US6214427B1 (en) * 1998-08-28 2001-04-10 General Electric Company Method of making an electronic device having a single crystal substrate formed by solid state crystal conversion
US6613906B1 (en) * 2000-06-06 2003-09-02 Geneva Pharmaceuticals, Inc. Crystal modification
US20020177680A1 (en) * 2000-08-23 2002-11-28 Hubbell Jeffrey A. Novel polymer compounds
US6475942B1 (en) * 2000-09-05 2002-11-05 General Electric Company Conversion of polycrystalline alumina to single crystal sapphire using molybdenum doping
SK13822003A3 (sk) * 2001-04-09 2004-09-08 Teva Pharmaceutical Industries Ltd. Polymorfné formy chloridu fexofenadínu
US7700779B2 (en) * 2001-06-18 2010-04-20 Dr. Reddy's Laboratories Limited Crystalline forms of fexofenadine and its hydrochloride
US20090211514A1 (en) * 2008-02-26 2009-08-27 Lehigh University Single crystal conversion process

Also Published As

Publication number Publication date
HK1137742A1 (en) 2010-08-06
EP1178041A1 (en) 2002-02-06
HK1098467A1 (en) 2007-07-20
US7662835B2 (en) 2010-02-16
US7138524B2 (en) 2006-11-21
CA2449419C (en) 2011-09-06
US20040014976A1 (en) 2004-01-22
CN1907967A (zh) 2007-02-07
JP2002255936A (ja) 2002-09-11
US20020193601A1 (en) 2002-12-19
FI964565A0 (fi) 1996-11-14
HUT76134A (en) 1997-06-30
CA2189007A1 (en) 1995-11-23
EP0766668A1 (en) 1997-04-09
US20020193603A1 (en) 2002-12-19
ES2176329T3 (es) 2002-12-01
US20030045721A1 (en) 2003-03-06
CA2585705A1 (en) 1995-11-23
US20070021462A1 (en) 2007-01-25
US20010012896A1 (en) 2001-08-09
NO964859L (no) 1996-11-15
CA2585705C (en) 2012-04-17
EP0766668B1 (en) 2002-07-17
PT766668E (pt) 2002-11-29
US7135571B2 (en) 2006-11-14
US20080167469A1 (en) 2008-07-10
US7666881B2 (en) 2010-02-23
WO1995031437A1 (en) 1995-11-23
IL134917A0 (en) 2001-05-20
DE69527429D1 (de) 2002-08-22
JP4503909B2 (ja) 2010-07-14
JP4503907B2 (ja) 2010-07-14
CA2189007C (en) 2004-03-02
HU9603167D0 (en) 1997-01-28
CN1907967B (zh) 2012-07-04
US20010025106A1 (en) 2001-09-27
US20070021461A1 (en) 2007-01-25
AU693892B2 (en) 1998-07-09
JP2010120969A (ja) 2010-06-03
JPH10500134A (ja) 1998-01-06
AU2426595A (en) 1995-12-05
US20080167471A1 (en) 2008-07-10
DE69527429T2 (de) 2003-03-20
ATE220667T1 (de) 2002-08-15
US20010014741A1 (en) 2001-08-16
CN1623985A (zh) 2005-06-08
US20020193600A1 (en) 2002-12-19
CA2449419A1 (en) 1995-11-23
JP2002255935A (ja) 2002-09-11
CN1148849A (zh) 1997-04-30
IL113747A (en) 2001-05-20
EP2354125A1 (en) 2011-08-10
JP2002308849A (ja) 2002-10-23
NO964859D0 (no) 1996-11-15
DK0766668T3 (da) 2002-10-28
IL134917A (en) 2001-07-24
IL113747A0 (en) 1995-08-31
JP4503908B2 (ja) 2010-07-14
HU227676B1 (en) 2011-11-28
JP2002316978A (ja) 2002-10-31
NO315319B1 (no) 2003-08-18
FI964565A (fi) 1996-11-14
JP2002308850A (ja) 2002-10-23

Similar Documents

Publication Publication Date Title
MX9605613A (es) Procedimiento para preparar formas anhidras e hidratadas de derivados de piperidina antihistaminica, polimorfos y pseudomorfos de los mismos.
HU9301361D0 (en) Method for producing 4-aryl-piperazines and 4-aryl-piperidines
SG49055A1 (en) Heterocyclic-cyclic amine derivatives
HU9601857D0 (en) New benzyl-piperidine- or -tetrahydro-pyridine derivatives and processes for producing them
BG105028A (en) Bridged indenopyrrolocarbazoles
FI971609A (fi) Menetelmä 4a,5,9,10,11,12-heksahydro-6H-bentsofuro-(3a,3,2-ef)(2)-bentsatsepiinijohdannaisten valmistamiseksi
TW362096B (en) Novel piperidine derivatives and the process for preparing the same
YU12000A (sh) Supstituisani 1,2,3,4,5,6-heksahidro-2,6-metano-3-benzazocin -10-oli, postupak za njihovo pripremanje i njihova primena kao lekova
IN187760B (es)
HU906010D0 (en) New substituted alkyl-piperidine derivatives
MX9500228A (es) N-oxidos de 4-arilpiperazinas y 4-arilpiperidinas.
IL158356A0 (en) Benzoheterocycles
MXPA03006057A (es) Proceso para preparar (+) trans-4-p-fluorofenil -3 hidroximetil.
ZA983231B (en) Substituted benzyloxyimino compounds.
UA66859C2 (uk) Спосіб стереохімічно контрольованого одержання ізомерно чистих високозаміщених азациклічних сполук
ES8505363A1 (es) Un procedimiento para preparar una 3-(2-furoil)-5-2,6-dimetil-4-(2-nitrofenil)-1,4-dihidropiridina
IT1256925B (it) Impiego di frammenti o/e di derivati della timosina alfa 1.
MY127539A (en) Bridged indenopyrrolocarbazoles
DE59911958D1 (de) Fluorierte 3,4-dihydrochinolin-derivative als nos-inhibitoren
ZA953930B (en) Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives polymorphs and pseudomorphs